The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
The December 2022 edition of The Spark features exciting new company updates including:
Lantern was ranked as the 16th (out of 380) most productive company for the use of AI in drug discovery by BioPharmaTrend, a top news provider of advanced technologies and AI for biopharma and biotech.
1) Lantern has activated a third Harmonic™ clinical trial site, New York Cancer and Blood Specialists, which will host the trial at 8 different locations across New York.
2) Harmonic™ in the news - The Harmonic™ trial was recently featured in a clinical trial spotlight article on OncLive, a high impact news site for oncologists about oncology news, clinical trials, and drug candidates. Read the full article here.
During Lung Cancer Awareness Month, Lantern partnered with the lung cancer advocacy group, Breath of Hope Kentucky (BOHKY), to raise awareness of issues facing never-smokers with lung cancer and to drive patient awareness for the Harmonic™ trial.
What’s next: Next year, in collaboration with BOHKY, we will continue to share additional survivor stories of never-smokers with lung cancer, which will further drive awareness of the Harmonic™ trial in the never smoker-lung cancer community.
Triple negative breast cancer (TNBC) is one of the most aggressive and malignant forms of breast cancer. Patients with TNBC have urgent needs for new therapies as they have no effective standard-of-care (SOC) therapy.
New LP-184 results were presented at the San Antonio Breast Cancer Symposium (SABCS) that demonstrated its anti-tumor potency in preclinical TNBC models:
Go deeper: In addition to LP-184’s preclinical anti-tumor efficacy for primary TNBC tumors, LP-184 may also have added therapeutic potential to treat brain metastases (brain mets.) from TNBCs, which are found in ~14% of TNBC patients at their initial diagnosis.
Each year in the US, there are approximately 8,000 newly diagnosed TNBC patients with an additional 21,000 relapsed TNBC patients, representing an annual market potential of up to $1.7 billion USD.
New LP-284 preclinical data for mantle cell lymphoma (MCL), an aggressive subtype of B-cell non-Hodgkins lymphoma (NHL), were recently presented at the American Society of Hematology (ASH) annual meeting.
Why it matters: Therapies for aggressive NHL’s, including MCL and double hit lymphoma’s (DHL), rarely achieve cures and have a high percentage of relapse and resistance. There are significant needs for additional late stage options for these patients.
In the US and Europe, MCL and DHL are diagnosed in approximately 9,000 patients each year and have an estimated annual market potential of $1.2 billion USD.
This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.